Maqola

Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy

Guojun ChenCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095;Zhitong ChenDepartment of Mechanical and Aerospace Engineering, University of California, Los Angeles, CA 90095;Di WenCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095;Zejun WangCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095;Hongjun LiCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095;Yi ZengCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095;Gianpietro DottiLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514;Richard E. WirzDepartment of Mechanical and Aerospace Engineering, University of California, Los Angeles, CA 90095;Zhen GuCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095;

2020en

ABI

Annotatsiya

Despite the promise of immune checkpoint blockade (ICB) therapy against cancer, challenges associated with low objective response rates and severe systemic side effects still remain and limit its clinical applications. Here, we described a cold atmospheric plasma (CAP)-mediated ICB therapy integrated with microneedles (MN) for the transdermal delivery of ICB. We found that a hollow-structured MN (hMN) patch facilitates the transportation of CAP through the skin, causing tumor cell death. The release of tumor-associated antigens then promotes the maturation of dendritic cells in the tumor-draining lymph nodes, subsequently initiating T cell-mediated immune response. Anti-programmed death-ligand 1 antibody (aPDL1), an immune checkpoint inhibitor, released from the MN patch further augments the antitumor immunity. Our findings indicate that the proposed transdermal combined CAP and ICB therapy can inhibit the tumor growth of both primary tumors and distant tumors, prolonging the survival of tumor-bearing mice.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.1073/pnas.1917891117

Iqtiboslar va manbalar

7 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar